Guggenheim raised the firm’s price target on Spyre Therapeutics to $50 from $44 and keeps a Buy rating on the shares, citing “promising” pre-clinical data presented at the ECCO meeting for SPY001 and SPY002. The firm Spyre Spyre “a highly interesting next-gen IBD company we think investors should be paying attention to.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYRE:
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Spyre Therapeutics on SY001 half-life extension
- Spyre Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- Spyre Therapeutics reports Q4 EPS ($4.05), consensus (78c)
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
